Rigel Pharmaceuticals announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA in patients with mutated isocitrate dehydrogenase-1 acute myeloid leukemia. REZLIDHIA is a potent, selective, oral, small-molecule inhibitor of mIDH11, designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells, that is approved for the treatment of relapsed or refractory mIDH1 AML.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals enters license and supply agreement with Kissei Pharma
- Rigel Pharmaceuticals price target raised to $17 from $1.75 at B. Riley
- Rigel Pharmaceuticals target adjusted to $57 from $15 at H.C. Wainwright
- Rigel Pharmaceuticals reports Q2 EPS (6c), consensus (29c)
- Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update